We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
In the latest trading session, Teladoc (TDOC - Free Report) closed at $22.46, marking a -1.45% move from the previous day. This change lagged the S&P 500's 0.57% loss on the day. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 1.04%.
Heading into today, shares of the telehealth services provider had lost 4.28% over the past month, lagging the Medical sector's loss of 0.85% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from Teladoc as it approaches its next earnings release. On that day, Teladoc is projected to report earnings of -$0.38 per share, which would represent year-over-year growth of 15.56%. Our most recent consensus estimate is calling for quarterly revenue of $663.6 million, up 8.54% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.36 per share and revenue of $2.63 billion, which would represent changes of +98.39% and +9.24%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Teladoc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Teladoc (TDOC - Free Report) closed at $22.46, marking a -1.45% move from the previous day. This change lagged the S&P 500's 0.57% loss on the day. Meanwhile, the Dow lost 0.05%, and the Nasdaq, a tech-heavy index, lost 1.04%.
Heading into today, shares of the telehealth services provider had lost 4.28% over the past month, lagging the Medical sector's loss of 0.85% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from Teladoc as it approaches its next earnings release. On that day, Teladoc is projected to report earnings of -$0.38 per share, which would represent year-over-year growth of 15.56%. Our most recent consensus estimate is calling for quarterly revenue of $663.6 million, up 8.54% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.36 per share and revenue of $2.63 billion, which would represent changes of +98.39% and +9.24%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Teladoc. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Teladoc is currently sporting a Zacks Rank of #3 (Hold).
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 180, which puts it in the bottom 29% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow TDOC in the coming trading sessions, be sure to utilize Zacks.com.